These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 36466929

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. 18 F-FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma.
    Wang S, Di S, Lu J, Xie S, Yu Z, Liang Y, Gong T.
    Thorac Cancer; 2023 Aug; 14(24):2338-2349. PubMed ID: 37424279
    [Abstract] [Full Text] [Related]

  • 43. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY, Lee HJ, Kim YT, Kang CH, Jang BG, Chung DH, Goo JM, Park CM, Lee CH, Kang KW.
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [Abstract] [Full Text] [Related]

  • 44. 18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer.
    Hu B, Chen W, Zhang Y, Shi H, Cheng D, Xiu Y.
    Ann Nucl Med; 2020 May; 34(5):322-328. PubMed ID: 32130663
    [Abstract] [Full Text] [Related]

  • 45. Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China.
    Hou H, Wang Y, Sun D, Zhu J, Jiang M, Zhang X, Zhou N, Zhang C, Li T, Zhang X.
    Invest New Drugs; 2023 Feb; 41(1):86-92. PubMed ID: 36508040
    [Abstract] [Full Text] [Related]

  • 46. Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer.
    Liu C, Zhao W, Xie J, Lin H, Hu X, Li C, Shang Y, Wang Y, Jiang Y, Ding M, Peng M, Xu T, Hu A, Huang Y, Gao Y, Liu X, Liu J, Ma F.
    Front Immunol; 2023 Feb; 14():1115291. PubMed ID: 36875128
    [Abstract] [Full Text] [Related]

  • 47. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A, Toschi L, Rossi S, Finocchiaro G, Grizzi F, Mazziotti E, Qehajaj D, Rahal D, Lopci E.
    Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
    [Abstract] [Full Text] [Related]

  • 48. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
    Burger IA, Casanova R, Steiger S, Husmann L, Stolzmann P, Huellner MW, Curioni A, Hillinger S, Schmidtlein CR, Soltermann A.
    J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566
    [Abstract] [Full Text] [Related]

  • 49. Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.
    Romine PE, Martins RG, Eaton KD, Wood DE, Behnia F, Goulart BHL, Mulligan MS, Wallace SG, Kell E, Bauman JE, Patel SA, Vesselle HJ.
    BMC Cancer; 2019 Jan 14; 19(1):70. PubMed ID: 30642285
    [Abstract] [Full Text] [Related]

  • 50. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
    Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY.
    Eur J Nucl Med Mol Imaging; 2010 Apr 14; 37(4):691-8. PubMed ID: 19915840
    [Abstract] [Full Text] [Related]

  • 51. Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
    Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, Govindan R, Torigian DA, Karp JS, Yu JQ, Subramaniam RM, Halvorsen RA, Siegel BA, ACRIN 6678 Research team, MK-0646-008 Research team.
    J Nucl Med; 2015 Aug 14; 56(8):1137-43. PubMed ID: 25908829
    [Abstract] [Full Text] [Related]

  • 52. Promising Candidate Prognostic Biomarkers in [18F]FDG PET Images: Evaluation in Independent Cohorts of Non-Small Cell Lung Cancer Patients.
    Hovhannisyan-Baghdasarian N, Luporsi M, Captier N, Nioche C, Cuplov V, Woff E, Hegarat N, Livartowski A, Girard N, Buvat I, Orlhac F.
    J Nucl Med; 2024 Apr 01; 65(4):635-642. PubMed ID: 38453361
    [Abstract] [Full Text] [Related]

  • 53. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer.
    Zhao ZR, Yang CP, Chen S, Yu H, Lin YB, Lin YB, Qi H, Jin JT, Lian SS, Wang YZ, You JQ, Zhai WY, Long H.
    Oncoimmunology; 2021 Apr 01; 10(1):1996000. PubMed ID: 34712513
    [Abstract] [Full Text] [Related]

  • 54. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
    Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Langen HJ, Bares R.
    Eur J Nucl Med Mol Imaging; 2007 Apr 01; 34(4):463-71. PubMed ID: 17103167
    [Abstract] [Full Text] [Related]

  • 55. Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Xu X, Sun ZY, Wu HW, Zhang CP, Hu B, Rong L, Chen HY, Xie HY, Wang YM, Lin HP, Bai YR, Ye Q, Ma XM.
    Radiat Oncol; 2021 Jul 19; 16(1):132. PubMed ID: 34281566
    [Abstract] [Full Text] [Related]

  • 56. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan 19; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 57. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH, Ahn HK, Ahn MJ, Ahn YC, Kim J, Shim YM, Choi JY.
    AJR Am J Roentgenol; 2015 Sep 19; 205(3):623-8. PubMed ID: 26295651
    [Abstract] [Full Text] [Related]

  • 58. The Predictive Value of Early In-Treatment 18F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Usmanij EA, Natroshvili T, Timmer-Bonte JNH, Oyen WJG, van der Drift MA, Bussink J, Geus-Oei LF.
    J Nucl Med; 2017 Aug 19; 58(8):1243-1248. PubMed ID: 28336778
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Subtype-Guided 18 F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.
    Wu S, Wang Y, Li J, Zhang N, Mo M, Klimberg S, Kaklamani V, Cochet A, Shao Z, Cheng J, Liu G.
    Oncologist; 2020 Apr 19; 25(4):e626-e633. PubMed ID: 32297448
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.